We have the ability to create any human cell type and manufacture it with consistency at scale. This unlocks unparalleled opportunities in cell therapy.
The possibilities for novel cures are endless.
The biggest hurdle in cell therapy today is access to consistent batches of human cell types at scale. Therapeutic development needs trillions of cells at an affordable cost in order to generate medicines that are accessible to millions of patients. bit.bio’s cell coding platform is able to provide a source of defined human cell types that are inherently consistent and scalable. We believe that our approach also has the potential to reduce the cost of cell therapies by up to two orders of magnitude.
Therapeutic development and manufacture needs to scale to trillions of cells to generate enough doses of a therapy that can be deployed to millions of patients.
Our platform provides partners with the ability to create new, inherently consistent and scalable cell types to form the basis of a cell therapy. By solving the cell problem, our partners are enabled to shift focus from “How are we going to make enough cells to treat one patient?” to "How can we ensure our therapeutic can treat every patient?".
Collaboration with BlueRock Therapeutics
In August 2023, bit.bio announced a collaboration and option agreement with BlueRock Therapeutics for the discovery and manufacture of iPSC-derived regulatory T cells
Collaboration with The Michael J. Fox Foundation
Multi-year collaboration agreement with The Michael J. Fox Foundation (MJFF) to generate human cell products for research and drug discovery in Parkinson’s disease
Synthego and bit.bio expand strategic partnership
To build a platform for the development of safer and more efficient genetic engineering of human cells for cell therapies
bit.bio announced as inaugural partner of Ginkgo's Technology Network
As a Network partner, bit.bio’s ioCells portfolio of human cells for research and drug discovery can be integrated into Ginkgo’s platform ecosystem